Dupilumab (Dupixent®) for prurigo nodularis. HTA ID: 23043

Assessment Status Rapid Review Complete
HTA ID 23043
Drug Dupilumab
Brand Dupixent®
Indication Dupilumab (Dupixent®) is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 21/07/2023
Rapid review completed 24/08/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.